The patient’s perspective on the symptom and everyday life impact of AL amyloidosis

References

• Kyle RA. Amyloidosis: a convoluted story. Br J Haematol 2001;114:529–38
   PubMed Web of Science ®Google Scholar
• Comenzo RL. Current and emerging views and treatments of systemic immunoglobulin light-chain (AL) amyloidosis. Contrib Nephrol 2007;153:195–210
   PubMedGoogle Scholar
• Grateau G, Stankovic K. Diagnosis and classification. In: Gertz MA, Rajkumar SV, eds. Amyloidosis: diagnosis and treatment. New York: Humana Press; 2010:33–48
   Google Scholar
• Lebovic D, Hoffman J, Levine BM, Hassoun H, Landau H, Goldsmith Y, Maurer MS, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008;143:369–73
   PubMed Web of Science ®Google Scholar
• Brown MP, Walls RS. Amyloidosis of immunoglobulin origin: useful treatment? Med J Aust 1990;152:95–7
   PubMed Web of Science ®Google Scholar
• Chertow GM, Trimbur T, Karlson EW, Lazarus JM, Kay J. Performance characteristics of a dialysis-related amyloidosis questionnaire. J Am Soc Nephrol 1996;7:1235–40
   PubMed Web of Science ®Google Scholar
• Coles GA, Williams JD. What is the place of peritoneal dialysis in the integrated treatment of renal failure? Kidney Int 1998;54:2234–40
   PubMed Web of Science ®Google Scholar
• Drent G, Graveland C W, Hazenberg BP, Haagsma EB. Quality of life in patients with familial amyloidotic polyneuropathy long-term after liver transplantation. Amyloid 2009;16:133–41
   PubMed Web of Science ®Google Scholar
• Klersy C, Callegari A, Giorgi I, Sepe V, Efficace E, Politi P, Pavia Working Group on QoL in Organ Transplant. Italian translation, cultural adaptation and validation of KDQOL-SF, version 1.3, in patients with severe renal failure. J Nephrol 2007;20:43–51
   PubMed Web of Science ®Google Scholar
• Mazzantini D, Pazzagli M, Cagno MC, Menconi G, Palla, A. Long-term survival in primary amyloidosis of the laryngotracheobronchial tract by treating complications only. Monaldi Arch Chest Dis 2000;55:114–6
   PubMedGoogle Scholar
• Roy A, Roy V. Primary systemic amyloidosis. Early diagnosis and therapy can improve survival rates and quality of life. Postgrad Med 2006;119:93–9
   PubMed Web of Science ®Google Scholar
• Seldin DC, Anderson JJ, Skinner M, Malek K, Wright DG, Quillen K, Finn K, et al. Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65. Blood 2006;108:3945–7
   PubMed Web of Science ®Google Scholar
• Seldin DC, Anderson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K, Finn KT, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood 2004;104:1888–93
   PubMed Web of Science ®Google Scholar
• Tuglular S, Yalcinkaya F, Paydas S, Oner A, Utas C, Bozfakioglu S, Ataman R, et al. A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant 2002;17:2003–5
   PubMed Web of Science ®Google Scholar
• Joffe H, Yardley L. Content and thematic analysis. In: Marks D, Yardley, L, eds. Research methods for clinical and health psychology. London: Sage; 2004:56–68
   Google Scholar
• Caccialanza R, Palladini G, Klersy C, Bonardi C, Cameletti B, Cereda E, Cameletti B, et al. Nutritional status and quality of life in outpatients with systemic immunoglobulin light-chain amyloidosis (AL) at diagnosis. Ann Hematol 2012;91:399–406
   PubMed Web of Science ®Google Scholar
• Gillmore J, Cocks K, Gibbs S, Sattianayagam PT, Lane T, Lachmann H, Schey S, et al. Cyclophosphamide, thalidomide and dexamethasone (CTD) versus melphalan plus dexamethasone (MD) for newly-diagnosed systemic AL amyloidosis – results from the UK Amyloidosis Treatment Trial. Blood 2009;114:1120
   Web of Science ®Google Scholar
• Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 1995;273:59–65
   PubMed Web of Science ®Google Scholar